Correlation Between NextCure and Cyclerion Therapeutics

Can any of the company-specific risk be diversified away by investing in both NextCure and Cyclerion Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NextCure and Cyclerion Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between NextCure and Cyclerion Therapeutics, you can compare the effects of market volatilities on NextCure and Cyclerion Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NextCure with a short position of Cyclerion Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of NextCure and Cyclerion Therapeutics.

Diversification Opportunities for NextCure and Cyclerion Therapeutics

0.35

Correlation Coefficient

NextCure  Cyclerion Therapeutics

Weak diversification

The 3 months correlation between NextCure and Cyclerion is 0.35. Overlapping area represents the amount of risk that can be diversified away by holding NextCure and Cyclerion Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cyclerion Therapeutics and NextCure is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NextCure are associated (or correlated) with Cyclerion Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cyclerion Therapeutics has no effect on the direction of NextCure i.e., NextCure and Cyclerion Therapeutics go up and down completely randomly.

Pair Corralation between NextCure and Cyclerion Therapeutics

Given the investment horizon of 90 days NextCure is expected to under-perform the Cyclerion Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, NextCure is 2.32 times less risky than Cyclerion Therapeutics. The stock trades about -0.16 of its potential returns per unit of risk. The Cyclerion Therapeutics is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  345.00  in Cyclerion Therapeutics on December 30, 2024 and sell it today you would lose (88.00) from holding Cyclerion Therapeutics or give up 25.51% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

NextCure  vs.  Cyclerion Therapeutics

NextCure

Risk-Adjusted Performance

Very Weak

Over the last 90 days NextCure has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Cyclerion Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Cyclerion Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy fundamental indicators, Cyclerion Therapeutics is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors.

Pair Trading with NextCure and Cyclerion Therapeutics

The main advantage of trading using opposite NextCure and Cyclerion Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NextCure position performs unexpectedly, Cyclerion Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclerion Therapeutics will offset losses from the drop in Cyclerion Therapeutics' long position.

The idea behind NextCure and Cyclerion Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.